## NCIC CLINICAL TRIALS GROUP

# LUNG

## NCIC CTG Lung Cancer Site Annual Meeting Agenda

Delta Chelsea Hotel, Toronto, Ontario Saturday, October 18, 2003 - 8:30 a.m. - 4:15 p.m. Room: Churchill Ballroom A

Chair: Dr. Frances Shepherd

8:30 a.m.	Results of	Dr. F. Shepherd		
8:45 a.m.	Review of Lung site Retreat		Dr. F. Shepherd	
Non-Sma	N-SMALL CELL LUNG CANCER			
9:00 a.m.	Surgical A	djuvant and Neoadjuvant Trials		
	BR.10 - Adjuvant navelbine/cisplatin in Stage I-II NSCLC		Dr. T. Winton	
	BR.16 -	Randomized placebo controlled trial of adjuvant Selenium in completely resected stage I NSCLC (ECOG)	Dr. F. Shepherd	
	BR.19 -	Randomized trial of adjuvant Iressa versus placebo after complete resection of Stage IB, II IIIA NSCLC	Dr. G. Goss	
	BR.22 -	Induction chemotherapy versus immediate surgery in Early stage NSCLC (SWOG)	Dr. Peter Ellis	
	BR. 23 -	Phase II trial of etoposide/cisplatin/XRT followed by Surgery and consolidation Taxotere for Pancoast tumours	Dr. S. Laurie	
	ES. 2 -	Palliative radiation for esophageal cancer	Dr. R. Wong	
10:00 a.m.	0:00 a.m. COFFEE BREAK			
10:45 a.m.	45 a.m. ADVANCED NSCLC			
	BR.15 -	Chemotherapy and radiotherapy +/- Iressa In Stage IIIB NSCLC (SWOG)	Dr. Y. Ung	
	BR.18 -	Taxol/carboplatin +/- BMS275291 in advanced NSCLC	Dr. N. Leighl	
	BR.21 -	Randomized trial of Tarceva versus placebo as 2nd or 3rd line treatment of advanced NSCLC	Dr. F. Shepherd	
	BR.17 -	Randomized comparison of Tomudex/cisplatin versus Cisplatin alone in Malignant Mesothelioma (EORTC)	Dr. M. Vincent	

#### 12:00 -1:00 **LUNCH**

#### 1:00 p.m. SMALL CELL LUNG CANCER

BR.20 - Randomized Phase II trial of ZD6474 versus placebo in responding patients with SCLC Dr. A. Arnold

### **NEW STUDIES UNDER CONSIDERATION AND NON-NCIC TRIALS**

PCI in NSCLC (RTOG) Dr. A. Sun

PCI in SCLC (RTOG) Dr. A. Sun

Possible trial of Taxotere +/-SCH66336 in second line NSCLC Dr. F. Shepherd

#### 2:15 **COFFEE BREAK**

Phase I trial of chemotherapy/XRT and ZD6126 in NSCLC Dr. A Brade

Possible randomized Phase II trial of Iressa versus standard Dr. R. Feld Combination chemotherapy as first-line treatment for N-SCLC

CTSU trial E4599 - Taxol/carbo +/- Avastin in stage IIIB Dr. F. Shepherd

and IV NSCLC